Scientists at the Icahn School of Medicine at Mount Sinai have developed an experimental immunotherapy that takes an unconventional approach to metastatic cancer: instead of going after cancer cells directly, it targets the cells that protect them. The study, published in the January 22 online issue of Cancer Cell, a Cell Press Journal [DOI 10.1016/j.ccell.2025.12.021], was conducted in aggressive preclinical models of metastatic ovarian and lung cancer. It points to a new strategy for treating advanced-stage solid tumors. In a strategy modeled after the famed Trojan horse, the treatment enters the tumors by targeting cells called macrophages that guard the cancer cells, disarms these protectors, and opens up the tumor’s gates for the immune system to enter and wipe out the cancer cells.

Financial penalties for Medicare readmissions have hit some hospitals harder than they should, for a seemingly unrelated reason: They happen to serve higher percentages of older adults who have chosen to enroll in Medicare Advantage plans.

Research assessed caregivers’ perceptions when witnessing episodes of terminal lucidity in children. The findings indicate that witnessing these episodes was regarded as a profoundly spiritual experience, capable of influencing personal belief systems. All caregivers shared what they had seen with others, receiving reactions of scepticism and/or acceptance.